Histological analysis did not reveal tissue damage in the lung, pancreas, or intestines of Renca-tumor-bearing mice treated with either DT2216 or PZ15227 (Supplementary Fig. 9m), indicating that Treg depletion and CD8+ T cell activation are relatively specific to the tumor microenvironment rather than being systemic and that targeting BCL-XL by PROTACs is a relatively safe and effective way to treat cancer. This evidence concerns the gene BCL2L1 and neoplasm.